Authors : Ringkangmai Liangkiuwiliu; Dr. Sonal Chand; Dr. Mohnyca Yumnam; Dr. Imran Khan

Volume/Issue : Volume 10 - 2025, Issue 6 - June

Google Scholar : https://tinyurl.com/5d6svjs8

DOI : https://doi.org/10.38124/ijisrt/25jun1227

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Introduction: Uterine fibroids, frequently referred to as leiomyomas or myomas, are the most widespread kind of benign uterine tumour. They can range in size, shape, and position within the uterus from unnoticeable nodules to huge masses that can deform the uterus. They are made up of cells of smooth muscles and fibrous connective tissue. Clinical manifestations include obstetric issues, infertility, bulk symptoms, abnormal bleeding, pelvic lumps, and pelvic discomfort. Over one third of women with leiomyomas will seek therapy as a result of their symptoms. It has a significant impact on 50% of women who are of reproductive age and 80% of women by beyond the age of 50. Aim: The aim of this study is to find out the effectiveness of Turmeric Green Tea on Physiological parameters and quality of life among women with uterine fibroids. Methodology: Intervention- Turmeric Green Tea. Here is a paraphrased version of your statement. Study Design: A randomized controlled trial utilizing a pre-test and post-test design with a placebo control group. Participants: Women diagnosed with uterine fibroids experiencing mild to moderate symptoms. Setting: Liangmai Community, Manipur. Outcome: This review result will show that Turmeric Green will be effective on physiological parameters and quality of life among women uterine fibroids.

Keywords : Uterine Fibroid/Leiomyomas/Uterine Tumour, Physiological Parameters, Quality of Life.

References :

1. Hazimeh D., et al. 2023. Green Tea and Benign Gynecologic Disorders: A New Trick for An Old Beverage? Nutrients. 2023 Mar 16;15(6):1439. PMID: 36986169 PMCID: PMC10054707 DOI: 10.3390/nu15061439. PubMed
2. Adham B., et al., (2022).The use of green tea in the treatment of symptomatic uterine fibroid. International Journal of Health Sciences, 6(S1), 3116–3135. https://doi.org/10.53730/ijhs.v6nS1.5353
3. V. R. Sinija and H. N. Mishra.(2008). Green tea: health benefits. Journal of Nutritional & Environmental Medicine December 2008; 17(4): 232–242. EBSCO
4. Ahmed, R. et al. (2016). Biological and Mechanistic Characterization of Novel Prodrugs of Green Tea Polyphenol Epigallocatechin Gallate Analogs in Human Leiomyoma Cell Lines. J. Cell. Biochem. 2016, 117, 2357–2369. [CrossRef] [PubMed]
5. Hendy A., et al., (2023). Fibroids and unexplained infertility treatment with epigallocatechin gallate: a natural compound in green tea (FRIEND) – protocol for a randomised placebo-controlled US multicentre clinical trial of EGCG to improve fertility in women with uterine fibroids. BMJ Open 14(1):e078989: DOI:10.1136/bmjopen-2023-078989
6. Zhang, D. et al. (2010). Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am. J. Obstet. Gynecol. 2010, 202, 289.e1–289.e9. [CrossRef] [PubMed]
7. Siblini. H., et.al., (2023). Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. Nutrients 2023, 15, 320. https://doi.org/10.3390/nu15020320
8. Rebekka B. et al. (2022). Effects of epigallocatechin gallate-enriched green tea extract capsules in uterine myomas: results of an observational study. Arch Gynecol Obstet. 2021 May;303(5):1235-1243. doi: 10.1007/s00404-020-05907-6. Epub 2021 Jan 2.
9. Roshdy, E. et al. (2013). A. Treatment of symptomatic uterine fibroids with green tea extract: A pilot randomized controlled clinical study. International Journal Women’s Health 2013, 5, 477–486.
10. Hewlings S.J., Kalman D.S. Curcumin: A Review of Its Effects on Human Health. Foods. 2017; 692. 10.3390/foods6100092. 29065496
11. Bai, et al.,(2023).The combination of natural compounds Crila and epigallocatechin gallate showed enhanced antiproliferative effects on human uterine fibroid cells compared with single treatments. Fertil Steril Sci® Vol. 4, No. 4, November 2023 2666-335X (http://creativecommons.org/licenses/by/4.0/).https://doi.org/10.1016/j.xfss.2023.09.004 
12. Siblini H. et al., (2021) EGCG for the treatment of unexplained infertility associated with UF: early safety assessment. Fertility and Sterility. 116(3), 2021.
13. Kenji T., et al., (2010). Inhibitory effect of curcumin on uterine leiomyoma cell proliferation. Gynaecological endocrinology. 27(7); https://doi.org/10.3109/09513590.2010.507287
14. Malik M., et al., (2009). Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression. Fertility and Sterility. 91(5), 2009: doi:10.1016/j.fertnstert.2008.03.045
15. Malik M., et al., (2023). Curcumin inhibits human leiomyoma xenograft tumor growth and induces dissolution of the extracellular matrix. Fertility and Sterility. 4(1); https://doi.org/10.1016/j.xfss.2022.10.004
16. Khadijeh. F., et al., (2023).A randomised controlled trial of the effects of curcumin on nitric oxide levels in women with premenstrual syndrome and dysmenorrhoea. Journal of herbal medicine.41; 2023; https://doi.org/10.1016/j.hermed.2023.100705
17. Porcoro G., et al., (2020). Vitamin D plus epigallocatechin: a novel promising approach for future uterine myomas. 2020 Mar;24(6):3344-3351.
18. https://doi: 10.26355/eurrev_202003_20702.
19. Mireillo D., at al., (2021). Uterine fibroid treatment: do we have new valid alternative: Vitamin D and EGCG. 2021 Apr;25(7):2843-2851. doi:10.26355/eurrev_202104_25537
20. Amir T., et al. (2023). Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhea: A randomized controlled trial. Physiological report. 2023 Jul;11(13):e15763. doi: 10.14814/phy2.15763.
21. Sharifipour F., et al., (2024). Effect of Curcumin on Dysmenorrhea and Symptoms of Premenstrual Syndrome: A Systematic Review and Meta-Analysis. Korean Journal of family Medicine.  2024 Mar;45(2):96-104.  doi: 10.4082/kjfm.23.0184.